EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Risk Factors for Ventilator-Associated Pneumonia in Patients Ventilated for Non-Pulmonary Conditions: A Prospective Multicenter Cohort Study (PULMIVAP)

Risikofaktoren für ventilatorassoziierte Pneumonie bei Patient:innen mit Beatmung aus nichtpulmonalen Gründen: prospektive multizentrische Kohortenstudie (PULMIVAP)

Laura Alagna, Liliane Chatenoud, Emanuele Palomba iD, Ilaria Olgiati, Federico Magni, Leonardo Mancabelli iD, Francesca Turroni iD, Chiara Abbruzzese iD, Chiara Buracchi iD, Cristina Bugarin iD, Matteo Filippini iD, Andrea Forastieri und 13 weitere

Open Forum Infectious Diseases · 31.10.2026 · 13 (11)

DOI: 10.1093/ofid/ofag677 ↗

Auf einen Blick

Bei 406 Patient:innen unter invasiver Beatmung wegen nichtpulmonaler Indikation traten VAP15 bei 36 % auf. Niedrigeres Risiko zeigte sich bei nichtneurologischer Diagnose, weiblichem Geschlecht und früher Antibiotikagabe.

Fragestellung

Welche Faktoren sind bei invasiv beatmeten Patient:innen mit nichtpulmonaler Indikation mit VAP innerhalb von 15 Tagen assoziiert?

Methode

Prospektive multizentrische Kohortenstudie in 8 Intensivstationen in Norditalien; Erwachsene mit IMV >48 Stunden; Beobachtung bis 15 Tage.

Ergebnisse

148/406 Patient:innen entwickelten VAP15 nach median 6 Tagen (IQR 4,0–7,5). Inzidenzrate 43,2 pro 1000 Beatmungstage (95 %-KI 36,4–49,9). aHR: nichtneurologische Diagnose 0,51, weiblich 0,52, frühe Antibiotika 0,65.

Einschränkungen

Kausalität kann aus den Beobachtungsdaten nicht abgeleitet werden.

Schlussfolgerung der Autor:innen

Bei Patient:innen mit IMV aus nichtpulmonalen Gründen waren nichtneurologische Diagnose, weibliches Geschlecht und frühe Antibiotikagabe mit niedrigerer beobachteter VAP-Inzidenz assoziiert; kausale Schlüsse sind nicht möglich.

Kernaussagen

  • VAP15 trat bei 36 % der 406 Patient:innen auf
  • Niedrigeres Risiko bei nichtneurologischer Diagnose und weiblichem Geschlecht
  • Frühe Antibiotikagabe war mit geringerem VAP15-Risiko assoziiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Kohortenstudie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 13.10.2026. Verfasst von Laura Alagna und 24 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ventilator-associated pneumonia (VAP) is a frequent complication of invasive mechanical ventilation (IMV), yet its determinants in patients ventilated for non-pulmonary indications remain poorly characterized.

Methods

Data were derived from the PULMIVAP multicenter prospective cohort (ClinicalTrial: NCT04849039), conducted in 8 Northern Italian intensive care units (January 2021–April 2024). All adults receiving IMV for non-pulmonary indications were enrolled if expected to require IMV >48 hours and antibiotic-free for ≥3 days preceding intubation. Clinical and therapeutic data were collected for up to 15 days of IMV; microbiological sampling was performed according to clinical indication. The primary outcome was time to first VAP within 15 days of IMV (VAP15). Associations between baseline characteristics, time-varying exposures, and VAP15 were evaluated. Thirty-day mortality from IMV initiation was a secondary outcome.

Results

Among 406 patients, 148 (36%) developed VAP15, at a median of 6 days (IQR 4.0–7.5) with an incidence rate of 43.2 per 1000 ventilator-days at risk (95% confidence intervals [95% CI], 36.4–49.9). Non-neurologic diagnosis (adjusted hazard ratio [aHR] 0.51; 95% CI, 0.31–0.86), female sex (aHR, 0.52; 95% CI, 0.36–0.75), and early antibiotic initiation (days 1–2 of IMV, aHR, 0.65; 95% CI, 0.45–0.93) were independently associated with lower risk of VAP15. Predominant pathogens were Staphylococcus aureus, Klebsiella spp., and Haemophilus influenzae; multidrug-resistant organisms were uncommon. VAP15 showed no competing relationship or significant association with mortality (overall, 20.4%).

Conclusions

In patients receiving IMV for non-pulmonary indications, non-neurologic diagnosis, female sex, and early antibiotic exposure were associated with lower observed VAP incidence, though causality cannot be inferred. Risk-stratified prevention strategies warrant further investigation into this population.

Schlagwörter

Stichwörter der Autor:innen

intensive care unitmechanical ventilationneurological disordersrisk factorsventilator-associated pneumonia

Autor:innen und Institutionen

  • Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Laboratory of Clinical Epidemiology, Department of Medical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Department of Infectious Diseases, Luigi Sacco Hospital, Regional Center for Infectious Diseases (CeReMI), Milan, Italy.
  • Centre for Multidisciplinary Action in Global Health (MAGH), University of Milan, Milan, Italy.
  • NeuroIntensive Care Unit, Department Neuroscience, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Department of Medicine and Surgery, University of Parma, Parma, Italy.

ORCID-Profile: Emanuele Palomba, Leonardo Mancabelli, Francesca Turroni, Chiara Abbruzzese, Chiara Buracchi, Cristina Bugarin, Matteo Filippini, Antonio Muscatello, Leonardo Terranova, Rosanna Vaschetto, Marco Ventura, Andrea Gori

Förderung

  • Italian Ministry of Health

Zitieren

APA

Alagna, L., Chatenoud, L., Palomba, E., Olgiati, I., Magni, F., Mancabelli, L., Turroni, F., Abbruzzese, C., Buracchi, C., Bugarin, C., Filippini, M., Forastieri, A., Gaipa, G., Fumagalli, R., Munari, M., Muscatello, A., Picetti, E., Terranova, L., Vaschetto, R., …, & PULMIVAP Study Group (2026). Risk Factors for Ventilator-Associated Pneumonia in Patients Ventilated for Non-Pulmonary Conditions: A Prospective Multicenter Cohort Study (PULMIVAP). Open Forum Infectious Diseases, 13(11). https://doi.org/10.1093/ofid/ofag677

Vancouver

Alagna L, Chatenoud L, Palomba E, Olgiati I, Magni F, Mancabelli L, et al. Risk Factors for Ventilator-Associated Pneumonia in Patients Ventilated for Non-Pulmonary Conditions: A Prospective Multicenter Cohort Study (PULMIVAP). Open Forum Infectious Diseases. 2026;13(11). doi:10.1093/ofid/ofag677

BibTeX
@article{Alagna2026,
  author = {Alagna, Laura and Chatenoud, Liliane and Palomba, Emanuele and Olgiati, Ilaria and Magni, Federico and Mancabelli, Leonardo and Turroni, Francesca and Abbruzzese, Chiara and Buracchi, Chiara and Bugarin, Cristina and Filippini, Matteo and Forastieri, Andrea and Gaipa, Giuseppe and Fumagalli, Roberto and Munari, Marina and Muscatello, Antonio and Picetti, Edoardo and Terranova, Leonardo and Vaschetto, Rosanna and Zoerle, Tommaso and Ventura, Marco and Citerio, Giuseppe and Gori, Andrea and Bandera, Alessandra and PULMIVAP Study Group, PULMIVAP Study Group},
  title = {Risk Factors for Ventilator-Associated Pneumonia in Patients Ventilated for Non-Pulmonary Conditions: A Prospective Multicenter Cohort Study (PULMIVAP)},
  journal = {Open Forum Infectious Diseases},
  year = {2026},
  volume = {13},
  number = {11},
  doi = {10.1093/ofid/ofag677}
}
Kostenlos starten →